Andrew Hall
Chief Executive Officer chez IMV INC.
Fortune : 12 $ au 31/12/2023
Profil
Andrew Hall is currently the Chief Executive Officer & Director at IMV, Inc. He previously worked as an Executive Director of Business Development at Celgene Corp.
and as an Executive Director of Global Women's Health at Merck & Co., Inc. Mr. Hall completed his undergraduate degree at the University of Melbourne and his graduate degree at RMIT University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
IMV INC.
0,05% | 20/03/2023 | 6 100 ( 0,05% ) | 12 $ | 31/12/2023 |
Postes actifs de Andrew Hall
| Sociétés | Poste | Début |
|---|---|---|
| IMV INC. | Chief Executive Officer | 04/08/2021 |
Anciens postes connus de Andrew Hall
| Sociétés | Poste | Fin |
|---|---|---|
| MERCK & CO., INC. | Corporate Officer/Principal | - |
| CELGENE | Corporate Officer/Principal | - |
Formation de Andrew Hall
| University of Melbourne | Undergraduate Degree |
| RMIT University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MERCK & CO., INC. | Health Technology |
| IMV INC. | Health Technology |
| Entreprise privées | 1 |
|---|---|
Celgene Corp.
 Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
